Skip to content
OpenCapital
Get started

Tarsus Pharmaceuticals, Inc. TARS Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares

Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares at other companies

WSFS Financial logo
WSFS FinancialWSFS
0-100%
Flagstar Bank logo
Flagstar Bank FLG
5.7M-39.3%
WaFd, Inc. logo
WaFd, Inc.WAFD
827.8K-1.8%
MSCI logo
MSCIMSCI
577K+63.9%
SBA Communications logo
SBA CommunicationsSBAC
14K-30.0%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
1.5M-13.8%

Other financials

Income statement

See full
Revenue$162.1M+107%
Gross profit$152.7M+109%
Operating income-$6.1M+76.7%
Net income-$7.0M+72.3%
EPS (diluted)-$0.16+75.0%

Balance sheet

See full
Cash & equivalents$104.2M-41.6%
Total debt$88.7M+22.5%
Total equity$349.0M+1.9%
Total assets$581.1M+16.1%

Cash flow

See full
Operating cash flow-$24.7M-19.4%
CapEx$5.8M+886%
Free cash flow-$30.5M-43.4%

Valuation

See full
Market cap$2.85B+41.1%
Enterprise value$2.83B+47.8%
P/S5.3×-3.3×

Profitability

See full
Gross margin42.7%—
Operating margin-9.5%-4.2pp
Net margin-9%-4.0pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-14%-5.2pp
Debt / equity0.3×0.0×
Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s sharebased compensation arrangement by sharebased payment award options nonvested number of shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s sharebased compensation arrangement by sharebased payment award options nonvested number of shares?
Tarsus Pharmaceuticals, Inc. (TARS) reported sharebased compensation arrangement by sharebased payment award options nonvested number of shares of 1.5M in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s sharebased compensation arrangement by sharebased payment award options nonvested number of shares changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s sharebased compensation arrangement by sharebased payment award options nonvested number of shares decreased by 13.8% year-over-year, from 1.8M to 1.5M.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s sharebased compensation arrangement by sharebased payment award options nonvested number of shares?
Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s sharebased compensation arrangement by sharebased payment award options nonvested number of shares has grown at a -0.7% compound annual growth rate (CAGR), from 1.4M to 1.4M.
What does sharebased compensation arrangement by sharebased payment award options nonvested number of shares mean?
This figure quantifies the total number of outstanding share-based payment awards that have not yet met the required vesting conditions. Monitoring this balance helps investors assess the future impact of equity-based compensation on share count and potential dilution.